首页> 外文期刊>Kidney and blood pressure research >Remote Ischemic Preconditioning Reduces the Risk of Contrast-Induced Nephropathy in Patients with Moderate Renal Impairment Undergoing Percutaneous Coronary Angiography: A Meta-Analysis
【24h】

Remote Ischemic Preconditioning Reduces the Risk of Contrast-Induced Nephropathy in Patients with Moderate Renal Impairment Undergoing Percutaneous Coronary Angiography: A Meta-Analysis

机译:远程缺血预处理降低了在经皮冠状动脉造影的中度肾损伤患者中对比肾病患者的风险:META分析

获取原文
           

摘要

Background/Aims: This meta-analysis evaluated the effects of remote ischemic preconditioning (RIPC) on the risk of contrast-induced nephropathy (CIN) in patients undergoing percutaneous coronary intervention/coronary angiography (PCI/CA). Methods: PubMed, Embase, and the Cochrane Central Register of Controlled Trials databases were searched for randomized controlled trials (RCTs) that assessed the effect of RIPC on CIN in patients undergoing PCI/CA. The main outcomes of interest were the incidence of CIN 48–72 h after CA, the levels of serum creatinine, cystatin C, neutrophil gelatinase-associated lipocalin, and estimated glomerular filtration rate (eGFR), mortality, and requirement of hemodialysis and rehospitalization. The analysis was conducted using the random-effect model due to the expected heterogeneity among different studies. Results: In total, 16 trials covering 2,048 patients were identified. By assessing the methodological quality of the included studies through the Cochrane risk of bias, we found that of the 16 RCTs, 3 had a low risk of bias, 6 a high, and 7 an unclear risk. The application of RIPC decreased the incidence of CIN (relative risk, RR, 0.50, 95% confidence interval, CI, 0.39–0.65; p 0.001). Subgroup analyses showed that RIPC decreased the incidence of CIN in patients with eGFR 60 mL/min/1.73 m2 (RR 0.53, 95% CI 0.38–0.75; p 0.001) but not in patients with eGRF ≥60 mL/min/1.73 m2 (RR 0.82, 95% CI 0.35–1.94; p = 0.66) at baseline. Furthermore, the increase in serum creatinine was significantly lower in patients with RIPC compared to control patients (standardized mean difference –1.41, 95% CI –2.46 to –0.35; p = 0.009). Conclusions: Based on 16 RCTs, this meta-analysis shows that RIPC can reduce the risk of CIN in patients with moderate renal impairment undergoing PCI/CA. However, this needs to be confirmed by further high-quality evidence.
机译:背景/目的:这种荟萃分析评估了远程缺血预处理(RIPC)对经皮冠状动脉介入/冠状动脉造影(PCI / CA)的患者对比肾病(CIN)的风险的影响。方法:对受控试验数据库进行了PubMed,Embase和Cochrane中央登记,用于评估PCI / CA患者RIPC对CIN的效果的随机对照试验数据库。感兴趣的主要结果是CA,血清肌酐,胱抑素,胱抑素C,中性粒细胞明胶酶相关脂素水平的发病率,以及估计肾小球过滤速率(EGFR),死亡率和血液透析和再生的要求。由于不同研究中的预期非均质性,使用随机效应模型进行分析。结果:鉴定了涵盖2,048名患者的16项试验。通过评估通过偏倚的Cochrane风险所包含的研究的方法论质量,我们发现16个RCT,3的偏倚风险低,6 A高,7个风险不明朗。 RIPC的应用降低了CIN的发生率(相对风险,RR,0.50,95%置信区间,CI,0.39-0.65; p <0.001)。亚组分析表明,RIPC降低了EGFR <60mL / min / 1.73m 2(RR 0.53,95%CI 0.38-0.75; P <0.001),但没有患有EGRF≥60ml/ min / 1.73的患者基线M2(RR 0.82,95%CI 0.35-1.94; p = 0.66)。此外,与对照患者(标准化平均差-1.41,95%CI -2.46至-0.35; p = 0.009),RIPC患者血清肌酐的增加显着降低。结论:基于16个RCT,该荟萃分析表明,RIPC可以降低接受PCI / CA的中度肾损伤患者的CIN风险。但是,这需要通过进一步的高质量证据来确认。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号